Special Drug Use-results Survey of Targretin Capsules combined with photo(chemo)therapy
Not Applicable
Recruiting
- Conditions
- Cutaneous T-cell lymphoma
- Registration Number
- JPRN-jRCT2031210625
- Lead Sponsor
- pharmacovigilance departmant
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
(1) Cases in which UV therapy is being performed and the combined use of bexarotene and UV therapy is started during the registration period.
However, if bexarotene has been used, cases that have not been administered for more than 4 weeks since the last administration
(2) Cases registered for the first time in this survey
(3) Patients who have been treated with UV therapy at a standard frequency (at least once a week) for about one month before the start of concomitant use with bexarotene, and the status of the treatment can be confirmed.
(4) Cases in which the consent of the patient was obtained
Exclusion Criteria
adult T-cell leukemia/lymphoma
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method